Change in patient reported end points
| Pranlukast (n=10) | Placebo (n=7) | Estimated median difference (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Before | After | Median difference | Before | After | Median difference | ||||
| β2 agonist use (puffs/day) | 3.6 | 2.3 | 1.4** | 3.6 | 3.1 | 0.3 | −1.4 (−2.4 to −4)** | ||
| Symptom score (scores/day) | 7.6 | 4.9 | 2.92-150 | 7.9 | 8.0 | −0.6 | −3.3 (−5.6 to −1.4)** | ||
| FEV1 (% pred) | 70.5 | 77.2 | −3.5 | 79.7 | 76.5 | 1.1 | 4.6 (−6.1 to 16.8) | ||
| Dmin (units) | 1.59 | 5.89 | −1.872-150 | 0.45 | 0.40 | −0.03 | 1.77 (0.45 to 10.0)2-150 | ||
Values are medians. Within groups the Wilcoxon signed rank test was used to give median differences. Comparison of treatment effects was by Mann-Whitney U test on delta values (after treatment minus before treatment) for pranlukast versus placebo treatment.
↵2-150 p<0.05; **p<0.01.